Reduced-dose anticoagulants feasible for extended VTE Tx

Reduced-dose anticoagulants feasible for extended VTE tx

(HealthDay)—For an extended duration, reduced-dose direct oral anticoagulants (DOACs) may be as effective as full-dose treatment for preventing recurrent venous thromboembolism (VTE), according to a review published online May 17 in the Journal of Thrombosis and Haemostasis.

Lakshman Vasanthamohan, M.D., from McMaster University in Hamilton, Canada, and colleagues conducted a systematic literature review to identify studies comparing reduced-dose DOACs with full-dose DOACs and or placebo in the extended phase of VTE treatment.

The researchers found that two trials met pre-specified inclusion criteria (5,847 patients for efficacy outcomes and 5,842 patients for safety outcomes). For preventing recurrent VTE at one year, reduced-dose DOACs were as effective as full-dose treatment (relative risk [RR], 1.12; 95 percent confidence interval [CI], 0.67 to 1.87) and more effective than aspirin or placebo (RR, 0.26; 95 percent CI, 0.14 to 0.46). For reduced-dose DOACs and aspirin or placebo, the risk of major or clinically relevant non-major bleeding events was similar (RR, 1.19; 95 percent CI, 0.81 to 1.77). For reduced- versus full-dose DOACs, there was a trend toward less bleeding (RR, 0.74; 95 percent CI, 0.52 to 1.05).

"Extended-duration treatment of VTE with reduced-dose DOAC may be as efficacious as full-dose treatment, with rates of major bleeding similar to treatment with aspirin or , but further long-term studies are needed," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

More information: Abstract/Full Text (subscription or payment may be required)

Copyright © 2018 HealthDay. All rights reserved.

Citation: Reduced-dose anticoagulants feasible for extended VTE Tx (2018, May 30) retrieved 24 June 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Direct oral anticoagulants plus antiplatelets effective in ACS


Feedback to editors